Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

We Highlight Blood Cancer Awareness Month

Our AML Franchise is looking to change the standard of care for patients with acute myeloid leukemia (AML).

September 2018 - Every 35 seconds, someone somewhere in the world receives the shattering news that they have been diagnosed with blood cancer.1 Leukemia is one type of blood cancer that affects the blood and bone marrow. Its most aggressive form is called acute myeloid leukemia (AML), with the lowest five-year survival rate of all leukemias.2

Still much work needs to be done to improve the current standard of care for AML

For more than 30 years, there was a lack of innovative treatment options approved for the treatment of AML. However, there have been a couple of drugs FDA-approved to treat various subtypes of AML since last year. While these new treatments represent important advances in treatment, there is still significant unmet need and much work to be done to improve the current standard of care for AML. This exactly is the focus of our AML Franchise and our message for Blood Cancer Awareness Month 2018!

Turn September red to raise awareness

Together with thousands of organisations and companies worldwide we want to raise much needed awareness to #fightbloodcancer. We try to help elevate a global call to action in order to educate society about the conditions' risk factors, sign and symptoms. In particular, our aim is to place a spotlight on areas where there is still a very high unmet need - and emphasize that we need to act now! Therefore Blood Cancer Awareness Month is a great opportunity to acknowledge that the aim of Daiichi Sankyo is to bring its oncology compounds in development to the market as soon as possible, ultimately improving the quality of life for patients and their families.